Pharmaceutical News

RSS

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

US study shows updated COVID vaccines cut hospitalization odds by 55%

The 2025-2026 COVID-19 vaccines were associated with 50% estimated effectiveness against COVID-19-associated emergency department and urgent care encounters among immunocompetent US adults. They were also linked to an estimated 55% effectiveness against COVID-19-associated hospitalization, providing added protection beyond existing immunity from prior infection or vaccination.

24 Jun 2026

Review outlines key strategies to overcome antibody drug conjugate resistance

The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

24 Jun 2026

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

From FairJourney Biologics S.A. 24 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

Statins may trigger muscle side effects by activating inflammatory danger signals

An experimental study in Science Advances shows that statins, primarily fluvastatin in these experiments, may promote low-level muscle myopathy by reducing isoprenoid-dependent protein prenylation rather than by cholesterol lowering. In primed muscle cells and mouse models, impaired YAP signaling, reduced glycolysis, NLRP3/caspase-1 activation, and nuclear FOXO accumulation increased atrogin-1, reduced protein synthesis, and weakened muscle function.

22 Jun 2026

GLP-1 medications may lower risk of multiple substance use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

21 Jun 2026

Heart failure treatments protect heart function during cancer therapy

The cardioprotective effects of heart failure treatments in patients with cancer were demonstrated today in a presentation at ESC Cardio-Oncology 2026, the annual conference of the European Society of Cardiology's Council of Cardio-Oncology.

19 Jun 2026

Computer models could design more effective probiotic supplements

Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, new University of Virginia School of Medicine research reveals.

18 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

Oral contraceptive pills may increase binge eating in some women

A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives - but not in all women.

17 Jun 2026

GLP-1 medications may reduce violent behavior in adults

The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers.

17 Jun 2026

Universities and hospitals repurpose existing drugs at significantly lower costs

Universities and hospitals are repurposing existing drugs through late-stage trials with funded costs up to 90% lower than those taking place in the pharmaceutical industry.

16 Jun 2026

Maternal RSV vaccine shows 68% protection against infant RSV hospitalization

In a test-negative case-control study of 274 hospitalized infants aged 90 days or younger, maternal RSVpreF vaccination was associated with 67.6% effectiveness against RSV-associated acute respiratory illness hospitalization. Protection was similar against RSV-linked lower respiratory tract disease, with the highest point estimate in the first month of life, although confidence intervals were wide.

16 Jun 2026